Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

Market Cap	10.28B +130.8%
Revenue (ttm)	1.18B +0.6%
Net Income	-53.07M
EPS	-0.10
Shares Out	538.65M
PE Ratio	n/a
Forward PE	14.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,907,300
Average Volume	37,700,681
Open	18.01
Previous Close	18.44
Day's Range	18.01 - 19.94
52-Week Range	6.64 - 22.63
Beta	0.60
RSI	70.81
Earnings Date	Apr 28, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,774
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300497

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -53.07 million, -80.50% less than in 2024.